Novo Nordisk and Heartseed Enter into Agreement to Develop Cell therapy for Heart Failure

By Shikha Kashyap

Pharma Deals Review: Vol 2021 Issue 7 (Table of Contents)

Published: 7 Jul-2021

DOI: 10.3833/pdr.v2021.i7.2625     ISSN: 1756-7874

Section: Licensing



With the focus of developing new treatment solutions for cardiovascular disease, Novo Nordisk entered into a licensing agreement with Heartseed for the latter’s stem cell-based therapy asset, HS-001, for heart failure...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details